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1. Introduction  
 
Adequate treatment of pain in the post operative period is essential to avoid 
unnecessary distress and to minimise the potential complications 
(Mackintosh, 2007).  
There have always been attempts to improve the management of pain 
treatment but, the management of post operative pain still needs 
improvement. Clinical, psychological and institutional consequences may 
arise from inadequate pain management (Hutchison, 2007). The 
unsatisfactory treatment of post operative pain can be the result of a 
unimodal therapy (Kehlet & Dahl, 1993). By combining pharmacological 
management and other measures, strategies should be developed to ensure 
maximum pain relief for each patient (Mackintosh, 2007). A multimodal or 
“balanced analgesia” appears to be the key for successful transition between 
anaesthesia and post-operative analgesia (Joris et al., 2001). The intra-
operative use of various adjuvant therapies that reduce the need for opioid 
and/or post-operative pain severity is an important part of balanced 
analgesia. The application of opioid- and non-opioid analgesics according to 
their pharmacokinetic characteristics, facilitate the transition from 
anaesthesia to analgesia (Joris et al., 2001). The advantages of balanced 
analgesia are based upon the fact that due to the additive or synergetic 
effects of different analgesics, an optimal analgesia can be achieved with 
minimal doses of individual therapeutic agents; it leads to the reduction of 
side effects (Kehlet & Dahl, 1993). A combination of opioid and non-opioid 
analgesics e.g. paracetamol is usually used as balanced analgesia. 
 
Paracetamol is an active metabolite of phenacetin and belongs to the group 
of non opioid analgesics. It exerts its analgesic effects by the peripheral and 
central inhibition of prostaglandins. The mechanism of action of paracetamol 
analgesia is not clearly understood but, it involves multiple factors. It is a 
potent inhibitor of prostaglandin synthesis with in the central nervous system 
(Piletta et al., 1990). Similarly it interferes with nociception associated with 
spinal NMDA (Bjorkman, 1995) receptor activation. This effect involves the 
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inhibitory action on spinal nitric oxide (NO) mechanisms (Bjorkman, 1995). 
Paracetamol is available as an oral, rectal and newly developed as an 
intravenous (Hahn et al., 2003) applicable form. The i.v. application of 
paracetamol avoids variability associated with gastric absorption and first-
pass hepatic metabolism (Back & Rogers, 1987), resulting in higher plasma 
concentration and greater analgesic efficacy than orally administered drug. 
The oral administration results in an unpredictable variation in plasma 
concentration compared with i.v. administration (Holmer et al., 2004). 
Moreover after a number of surgical procedures (intestinal, head and neck 
surgeries etc.), enteral application of analgesics is not possible. In such 
cases i.v. paracetamol is a good alternative to non-steroidal anti-
inflammatory drugs (Graham et al., 1999) and other non-opioid analgesics. 
Intra-operative administration of paracetamol has been shown to decrease 
pain with a morphine sparing effect (Binhas et al., 2004). 
 
There are two intravenous inject able forms of Paracetamol. The water 
soluble, inject able form Propacetamol; that is rapidly hydrolyzed to 
acetaminophen (paracetamol) in the blood by the enzymatic action of 
esterases. Hydrolysis of 2 g Propacetamol yields 1 g paracetamol 
(Bannwarth et al., 1992d; Flouvat et al., 2004).  
 
The second inject able form is a direct intravenous inject able form of 
paracetamol (e.g. Perfalgan®).1g of Paracetamol administered as 
Perfalgan® 
10 mg/ml is bioequivalent to 2 g Propacetamol with a better local safety. 
Perfalgan® is a ready-to-use formulation and must not be reconstituted in to 
a solution as Propacetamol (Flouvat et al., 2004).  
These studies indicate an optimal bioavailability of paracetamol by 
intravenous application and the synergetic effects to Cyclooxgenase-2- 
inhibitors (COX2- inhibitors) are reported which can be partly replaced by 
paracetamol and the low incidence of side effects makes i.v. paracetamol a 
good alternative drug for other analgesics. 
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The recommended dosage for the intravenous application of Perfalgan® is 
an infusion of 1g over 15 minutes. The aim of our study was to evaluate the 
pharmacokinetics of i.v. paracetamol after different infusion rates and in view 
of the results the optimization of dosage and mode of i.v. application of 
paracetamol. 
 
1.1 Non-opioid analgesics  
 
Antipyretic analgesic were developed about a hundred years ago and 
divided in to two groups; the acidic (aspirin-like drugs) and non-acidic 
(acetaminophen-phenazone-like) compounds (Brune & Neubert, 2001). The 
analgesics having a pKa-value (that is the pH- value at which the 50 % of the 
substance is found to be in dissociated form) of less than 5 are called acidic-
antipyretic-analgesics and those with a pka value of more than 5 are the 
non-acidic analgesic-antipyretics.  
Acidic- and non-acidic antipyretic analgesics possess different 
pharmacokinetic properties. The acidic-antipyretic-analgesics achieve high 
concentrations in tissues with low pH like inflamed tissue, which is assumed 
to account for their superior anti-inflammatory potency and also reach 
comparatively high concentrations in the stomach wall, kidney cortex and 
blood, resulting in the well-known side effects that occur with acidic 
compounds but not with paracetamol and phenazone (Brune & Neubert, 
2001).  
 
The non-acidic-group is further divided into chemical groups of pyrazolinone 
and aniline. The example of pyrazolinone includes Metamizol; and 
paracetamol  belongs to the aniline group. 
 
Another group of non-narcotic-antipyretic-analgesics includes the 
cyclooxygenase- (COX-) 2-inhibitors. The examples include Celecoxib, 






1.2 History  
 
In the ancient history from Egypt and Greece, the analgesic and antipyretic 
effects of willow bark are known for centuries. The modern era of salicylates 
starts from 1758 with a report by Edward Stone (“an account of the success 
of the bark of willow in the cure of agues”) sent to The Royal Society in 
London. The active ingredient of willow bark “salicine” was first isolated in 
1828 by Joseph Buchner, then by Henri Leroux, and also prepared from the 
oil of wintergreen (Gualtheria) and meadowsweet (Spirea ulmaria) by 
J.W.Lowig 1833, called “Spirsaure” which was already pure acetylsalicylic 
acid. It was also synthetised 1853 by Ch. Gerhardt and finally 1897 in 
Bayer´s laboratories by Felix Hoffmann, who also demonstrated its anti-
inflammatory efficacy(Jerie, 2006).  
 
The prototypes of antiphlogistic analgesics include acetylsalicylic acid 
(aspirin), acetanilide (the forerunner of acetaminophen), and phenazone. 
Advances in the knowledge of chemical structure of drugs in 19th-20th 
century along with the attempts to improve the effects and reduce the side 
effects of analgesics-antipyretics led to the development of other aspirin-like 
drugs called non-steroidal anti-inflammatory drugs (Brune & Niederweis, 
2007). 
 
 Most of the NSAIDs were initially organic acids, but later non-acidic 
compounds were discovered. The drug discovery of NSAIDs can be divided 
in to two periods the time span from the post-World War 2 till the 1970´s was 
the pre-prostaglandin period and thereafter up to the later part of the last 
century was the period in which the effects on the production of 
prostaglandin were considered during the drug-discovery process 
(Rainsford, 2007). 
In 1946, the Institute for the Study of Analgesic and Sedative Drugs awarded 
a grant to the New York City Department of Health to study the problems 
associated with analgesic agents. Bernard Brodie and Julius Axelrod were 
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assigned to investigate why non-aspirin agents were associated with the 
development of methemoglobinemia, a condition that decreases the oxygen-
carrying capacity of blood and is potentially lethal. In 1948, Brodie and 
Axelrod linked the use of acetanilide with methemoglobinemia and 
determined that the analgesic effect of acetanilide was due to its active 
metabolite paracetamol. They advocated the use of paracetamol, since it did 
not have the toxic effects of acetanilide (Brodie & Axelrod, 1948). 
 
1.3 Chemical Structure 
Paracetamol is virtually the sole survivor of the so-called “aniline derivatives” 
or “aniline analgesics”. These aniline derivatives include acetanilide, 
phenacetin and paracetamol (acetaminophen). Phenacetin and paracetamol 
are both derivatives of acetanilide (Bertolini et al., 2006) (Fig.1). 
 
Fig.1 Chemical structures of “aniline” analgesics  
 
 
Paracetamol consists of a benzene ring core, substituted by one hydroxyl 
group and the nitrogen atom of an amide group in the para pattern 
(Mutschler, 1991). The amide group is acetamide (ethanamide). It is an 
extensively conjugated system, as the lone pair on the hydroxyl oxygen, the 
benzene pi cloud, the nitrogen lone pair, the p-orbital on the carbonyl carbon 
and the lone pair on the carbonyl oxygen are all conjugated. The presence of 
two activating groups also makes the benzene ring highly reactive towards 
electorphilic aromatic substitution. As the substituents are ortho, para 
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directing and para with respect to each other, all positions on the ring are 
more or less equally activated. The conjugation also greatly reduces the 
basicity of the oxygen and the nitrogen, while making the hydroxyl acidic 
through delocalisation of charge developed on the phenoxide anion. 
 
1.4 Indications and applications 
 
In view of its proven efficacy and low toxicity paracetamol is used on a 
worldwide basis. The analgesic and antipyretic effects of paracetamol are 
accepted to be of therapeutic significance, while its anti-inflammatory and 
anti-rheumatic activities are negligible (Clissold, 1986). 
The spectrum of indications includes from the discomforts of the common 
cold over the post operative pain to the pain associated with malignancy. 
The analgesic efficacy of paracetamol is equivalent to that of aspirin, and its 
plasma levels required for the analgesic activity are higher than those 
needed for the antipyretic activity (Beck et al., 2000). 
As an analgesic and antipyretic paracetamol replaces aspirin especially in 
cases where aspirin is contraindicated. It has a broad tolerability and is of 
particular value in the treatment of patients in whom non-steroidal-anti-
inflammatory drugs (Graham et al., 1999) are contraindicated such as 
aspirin-sensitive asthmatics and people at risk of gastrointestinal 
complications (Prescott, 2000). 
Paracetamol is available in oral, rectal and intravenous applicable forms.  
Oral administration of paracetamol as part of multimodal pain management 
immediately post-operatively resulted in a huge and unpredictable variation 
in plasma concentration compared with the intravenous administration 
(Holmer et al., 2004). Intravenous administration of paracetamol either as 
intravenous acetaminophen or Propacetamol avoids variability associated 
with gastric absorption and first-pass hepatic metabolism, resulting in higher 
plasma concentrations and greater analgesic efficacy than orally 
administered drug (Jarde O & Boccard E, 1997).  
 
Propacetamol (Pro-Dafalgan® or Pro-Efferalgan®), inject able prodrug of 
paracetamol, is in many European countries the first inject able paracetamol-
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formula brought in the market. Perfalgan® is a newly developed intravenous 
applicable paracetamol of second generation.  
 
In reference to anaesthesiological pain management in peri-operative 
(Kehlet & Dahl, 1993) as well as in special (adjunctive) pain treatment, 
paracetamol is indicated as follows: 
• Treatment of moderate pain especially as an additive to other 
measurements. 
• As an opioid sparing drug to reduce the side effects associated 
with opioid analgesics (e.g. respiratory depression). 
• Treatment of fever for adults and children over 10 kg body weight. 
 
Apart from that the drug is indicated by patients with known pseudo allergy 
against Metamizol by patients with blood disorders (agranulocytosis by 
Metamizol), especially by children(Hedenmalm & Spigset, 2002). 
Lastly the i.v. analgesics like Prerfalgan® cover the gap created by the 
removal of COX2-inhibitors from the market. 
 
1.5 Side effects  
 
Paracetamol is a safe drug at appropriate dosage with a therapeutic index of 
approximately 10. The therapeutic dosage of paracetamol is 10-15mg/kg, 
and a dose of 7.5g in an adult or 150 mg/kg in a child are considered as the 
lowest acute dose capable of causing toxicity. 
The very low level of paracetamol binding to plasma proteins, together with 
its hepatic metabolism, mainly through glucuronide or sulphate conjugation, 
account for the low risk of drug interactions with paracetamol, particularly 
with antivitamin K. When added to a traditional NSAID, paracetamol 
enhances the analgesic effect or allows the use of lower doses (Bannwarth & 
Pehourcq, 2003). 
 
The safety of paracetamol was reported in patients with stable chronic liver 
disease showing no evidence of accumulation or hepatotoxicity after the 
administration of the drug in therapeutic doses (Benson, 1983). 
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A clinical significant damage of liver cells is rare after therapeutic doses of 
paracetamol however; the incidence of acute liver failure is reported even 
after therapeutic doses (Pearce & Grant, 2008). 
The side effects of paracetamol are usually associated with its overdoses but 
rare incidence of anaphalctoid reaction after therapeutic doses of 
paracetamol is also reported (Ayonrinde & Saker, 2000) 
Acute renal failure is not uncommon in paracetamol poisoning and appears 
to be unrelated to the degree of liver injury (Mour et al., 2005). However, 
there are many conditions which might play a role as influencing factor in 
causing renal complications after paracetamol overdoses; they include 
concomitant ingestion of nephrotoxic drugs, dehydration, chronic excessive 
dosing (von Mach et al., 2005) of acetaminophen, pre-existing renal or liver 
disease and multiple organ failure (von Mach et al., 2005). 
 
1.6 Mechanism of action 
 
The mechanism of action of paracetamol analgesia is not fully understood 
but involves multiple factors. It is a potent inhibitor of prostaglandin synthesis 
within the central nervous system (Piletta et al., 1991). 
The prostaglandins are lipid mediators. The formation of prostaglandins is 
catalysed by the enzyme cyclooxygenase (COX). COX is a bifunctional 
enzyme having both cyclooxygenase and peroxydase activities. 
Prostaglandins are involved in physiological functions of the body such as 
protection of the stomach mucosa, aggregation of platelets and regulation of 
kidney functions however; they also have pathological functions and involve 
in the processes of inflammation, pain and fever. In 1971, Sir John Vane 
demonstrated for the first time that the mechanism of action of aspirin and 
other non-steroidal anti-inflammatory drugs (Graham et al., 1999) is via 
inhibition of COX. A second cyclooxygenase (Brune & Neubert, 2001) was 
identified in 1991 by Simmon and his colleagues. The inflammatory 
mediators upregulate COX-2, increasing prostaglandin formation that 
intensify the inflammatory response(Botting, 2006). A third variant of COX 
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designated by some authors as COX-3 has been reported. This enzyme is 
produced by cyclooxygenase-1 gene, but retains intron 1 after transcription 
and translates into a cyclooxygenase enzyme with 34 additional amino acids. 
It is experimented in specific tissues and shows a high concentration in brain 
and heart. It is selectively inhibited by analgesic/antipyretic agents like 
paracetamol and NSAIDs, however not through COX-2-selective inhibitors. 
This enzyme is possibly a central mechanism for the analgesic/antipyretic 
effects of paracetamol (Chandrasekharan et al., 2002). 
 
The results obtained from paracetamol could not show systemically an 
effective inhibition of peripheral COX. A few positive results were obtained 
from in vitro tests (COX-1/COX-2-inhibition) on intact cells or human full 
blood. However as opposed to this finding, in vivo tests the peripheral COX-
2-inhibition through paracetamol should be very limited. This difference of in-
vivo- and in-vitro-effects can be due to the higher concentration of peroxides 
in inflamed tissue (Ouellet & Percival, 2001).  
 
Some reports suggest the modulation of the serotoninergic system as a 
possible mechanism of paracetamol antinociceptive activity and indicate that 
the drug may stimulate the activity of descending 5-HT pathways that inhibit 
the nociceptive signal transmission in the spinal cord (Bonnefont et al., 
2003). Other studies suggest a supraspinal target for acetaminophen's 
antinociceptive action and a central serotonergic mechanism of action for 
acetaminophen that is not stimulus-dependent (Pickering et al., 2007). 
The central mechanism of action of paracetamol is supported by the 
observations that paracetamol crosses the blood-brain barrier rapidly leading 
to a high concentration of the drug in cerebrospinal fluid (CSF) and a parallel 
time-course of paracetamol concentration in CSF and its analgesic effect 
(Bannwarth et al., 1992) 
 
Paracetamol also acts peripherally by blocking impulse generation within the 




Paracetamol is thought to have an analgesic effect by antagonising NMDA 
and substance P in the spinal cord. Analgesic effect also involves an 
inhibitory action on spinal nitric oxide mechanisms (Clissold, 1986; Piletta et 
al., 1991; Bjorkman, 1995).  
 
It is also reported that the analgesic effects of paracetamol involve the 
indirect activation of cannabinoid (CB) receptors; and in the central nervous 
system (CNS) paracetamol after its deacetylation to its primary amine (p-
aminophenol), conjugate with arachidonic acid to form N-
arachidonoylphenolamine. N-arachidonoylphenolamine is known to act as an 
endogenous CB. Thus paracetamol act as a pro-drug and the active form 




Paracetamol is rapidly absorbed after oral administration; peak plasma 
concentrations are reached in 30-60 minutes. The plasma half life of 
paracetamol with therapeutic doses is 2-4 hours but with toxic doses it may 
be extended to 4-8 hours. Paracetamol is rather evenly distributed in most of 
the body fluids. It is weakly bounded to the plasma proteins, and even in 
toxic doses only 20% - 50% of the substance is in a bounded form. By 
therapeutic doses, 90% -100% of the substance is found in the urine on first 
day of administration. Paracetamol is inactivated in liver, being conjugated to 
glucuronic acid (60%), sulphuric acid (35%) and cystines (3%). Minute 
quantities of hydroxylated and desacylated metabolites can also be detected. 
A small part of paracetamol is by cytochrom-450-dependant N-hydroxylation 
metabolised, that leads to the formation of N-acytylbenzochinonimin, a very 
reactive intermediate metabolite. This metabolite reacts normally with 
sulphydryl groups of glutathione, however after high doses of paracetamol, 
the glutathione stores of liver are used up. Under these conditions N-
acytlybenzochinonimin reacts with the sulphydryl groups of liver proteins in 
such an extent that liver necrosis can develop (Paul A.Insel, 1940). 
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Studies have shown oral paracetamol to be very effective and good tolerable 
for post operative pain management (Weil et al., 2007). However the use of 
paracetamol is limited to the treatment of mild to moderate pain or as a 
second-line-therapy many days after the operation. At an oral dose of 
1000mg paracetamol reaches its ceiling effect in adults. No increase in 
analgesic activity occurs by further increasing the doses (Woodbury DM., 
1965), but it does increase the toxicity.  
After oral doses the absorption of paracetamol is not uniform but after an i.v. 
administration the plasma concentration is predictable. 
 
After an infusion of paracetamol the maximum plasma concentration is much 
higher than that after oral doses, so that more of the substance can cross the 
blood-brain barrier. It can also explain the lack of Ceiling-Effect(Skoglund & 
Pettersen, 1991) after intravenous application of up to 2g of paracetamol. 
Intravenous acetaminophen exerted a dose-dependent central 
antinociceptive effect (Piguet et al., 1998). 
 
1.8 Current literature  
 
The pharmacologic effects of paracetamol are not directly related to the 
concentration of the drug in plasma but they are related rather to an effect 
compartment. The concentrations of the effect compartment equate 
approximately to cerebrospinal fluid (CSF) (Anderson & Gibb, 2007a). The 
time and CSF concentration of paracetamol show a correlation with its 
antipyretic effect (Kozer et al., 2007). 
Paracetamol permeates readily into the CSF of children. This enables the 
rapid central analgesic and antipyretic action of intravenous paracetamol 
(Kumpulainen et al., 2007). 
Intravenous paracetamol crosses the blood-brain barrier rapidly and the 
elimination half-life of paracetamol was shorter in plasma than in CSF. 
Antipyretic and probably analgesic effects of Paracetamol are at least in part 
centrally mediated. The time-course of paracetamol in CSF may parallel that 
of analgesic effect (Bannwarth et al., 1992). 
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Gregoire (Gregoire et al., 2007) showed that after repeated doses of 
paracetamol with a maximum dose of 4g/day, the plasma concentrations 
remained under the toxic range, indicating the absence of accumulation. 
In a study performed on children from neonates to adolescents to determine 
the age related changes in plasma and CSF equilibration half-time (Teq) of 
paracetamol showed that size rather than blood-brain-barrier maturation 
determines Teq changes with age in children (van der Marel et al., 2003). 
 
1.9 Aim of the trial 
 
The aim of the trial was to evaluate, whether similar or comparable 
efficacious CSF levels of Perfalgan® could be obtained after an infusion of 
1g over 60 minutes as compared to an infusion of 1g over 15 minutes in a 








This experimental procedure was performed on 10 female German domestic 
pigs. The approval of the experimental procedure was obtained from the 
local Animal Investigation Committee (Regierungspräsidium, Gießen) before 
starting the trial. The pigs were kept for one week under a phase of 
observation and familiarization, before the start of the experiment, in the 
animal experimental lab of the Philipps-University-Marburg. 
The pigs were randomized by a computerized random-number generator 
either in the group which received the Perfalgan® infusion in 15 minutes or 
in the group receiving the Perfalgan® infusion in 60 minutes.  
 
2.2 Pre medication and anaesthesia 
 
The pre medication was done with an intramuscular application of diazepam 
1mg/kg, ketamin 20mg/kg and atropine 0.2mg/kg bodyweight. 
An intravenous line was taken in one of the dorsal ear veins with a 20 gauge 
canula. The induction of anaesthesia was performed with an intravenous 
injection of disoprivan 2mg/kg and fentanil 0.5µg/kg bodyweight as repetitive 
bolus, followed by tracheal intubation. The animals were ventilated with a 
Dräger anaesthesia machine (Sulla 808 V) and an intermittent positive 
pressure ventilation mode with a mixture of oxygen in air at an inspiratory 
concentration (FiO2) of 50% was used. The anaesthesia was maintained 
with a continuous infusion of Disoprivan (Propofol®) 1% at a rate of 
10mg/kg/h and sufentanil 1µg/kg/h. No muscle relaxant was used. 
 
2.3 Infusion protocol 
 
The pigs were randomized in two groups. Group one (n=5) received an 
infusion of 1g Perfalgan over 15 minutes. In this group (15-min-group), 
plasma and CSF samples were taken at 15, 30, 60, 90, 120, 150, 180, and 
210 minutes after starting the infusion. 
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Group two (n=5) received an infusion of one gram of Perfalgan over 60 
minutes. In this group (60-min-group), the first plasma sample was taken 60 
minutes after starting the infusion and repeated after every 30 minutes up to 
210 minutes. The CSF samples in this group (60-min-group) were obtained 
at 90, 120, 150, 180, and 210 minutes after starting the infusion.  
 
Plasma samples were taken through a central venous catheter. In order to 
obtain the CSF, we performed a lumber puncture at the levels of second, 
third or fourth lumber vertebra with a 25 gauge spinal needle (Quincke 
needle 25G) and kept the needle in place. 
The samples were collected into tubes with no additives and transported to 
the central laboratory of the University Hospital Marburg immediately after 
the procedure. 
 
2.4 Laboratory Methods 
 
The laboratory measurement of paracetamol was performed with Synchron® 
- System(s) (Beckman Coulter, Inc.) with the help of acetaminophen (ACTM) 
reagent. ACTM reagent is used to measure ACTM concentration by a 
particle enhanced turbidimetric inhibition immunoassay method (Newman et 
al., 1992). A Particle-bound drug (PBD) binds to the analyte specific antibody 
(Ab) resulting in the formation of insoluble aggregates causing light scatter. 
Non particle-bound analyte in the patient sample competes with the PBD for 
the antibody binding sites, inhibiting the formation of insoluble aggregates. 
The System monitors the aggregate formation by measuring the change in 
the absorbance at 340 nanometers. This change in absorbance is inversely 
proportional to the concentration of ACTM based on a multi-point calibration 
curve. The same methods were applied for the measurements of 
paracetamol concentrations in plasma and CSF. 
 
The chemical reaction can be shown by the following equation. 




2.4.1 Analytic range 




Sample Type Conventional Units S.I. Units 
Serum or Plasma 10 – 300 µg/mL 66 – 1986 µmol/L 





Sensitivity is defined as the lowest measurable concentration which can be 
distinguished from zero with 95% confidence. 
Sensitivity for ACTM determination is 2.5 µg/mL (16 µmol/L).  
 
2.4.3 Specificity 
Most of the substances added at the concentrations from  50 µg/mL to 1000 
µg/mL to separate aliquots of a serum pool containing 40 µg/mL 




A compartmental analysis of the pharmacokinetic estimates was performed 
using the software packet TopFit (Thomae Optimized Pharmacokinetic 
Fitting Program), Version 2.0 (Heinzel G. et al., 1993). 
 
2.5.1 Pharmacokinetic model 
A two compartment model with first-order elimination and i.v. bolus dosing 
was used where plasma is the central compartment and brain is the 
peripheral compartment. The two compartment model fits better and is in 
accordance with the literature; moreover a three compartment model did not 




2.5.2 Weighting and goodness-of-fit 
The goodness-of-fit was evaluated by visual inspection of predicted vs. 
observed data and from plots of residuals. The individual weighting was 
performed for each measured value by the use of the mathematical 
algorithm from TopFit. 
 
2.5.3 Measured parameters 
 
Elimination half-life (t 1/2 beta), total clearance (Cl(t)), mean resident time 
(MRT), area under the curve (AUC) and volume of distribution at equilibrium 
(Vd(ss)) were calculated. 





3. Results  
 
3.1 Age, gender and body weights 
 
This experiment was performed on female pigs. The age of the animals in 
both groups were on an average about twelve weeks, with no relevant 
difference between the groups. The bodyweights of the animals in both of 
the groups were also comparable. The age and bodyweights of the subjects 
are shown in the following table below. 
 
 
Table 2. Age and weight of animals. 
Group Age of the animals Weight of the animals 
15-min 11 – 13 weeks 38.8 kg – 41.7 kg 
60-min 11 – 14 weeks 38.5 kg – 41.9 kg 
Legends: kg: kilogram; min: minutes. 
 
 
3.3 Plasma Levels of paracetamol 
 
The plasma levels of paracetamol were measured in individual animals at 
regular intervals. 
 
3.3.1 Individual Plasma Levels in 15-min-group 
 
The values of plasma concentration of Paracetamol obtained from individual 









Table3. Individual levels of Paracetamol observed in 15-min-group. 
Animal 
No. 
Plasma Levels [mg/l] 15-min-group 
 15min 30min 60min 90min 120min 150min 180min 210min 
1. 32.5 16.0 10.4 10.0     
2. 28.7 24.7 22.6 18.7 14.0 14.5 11.8  
3. 33.1 27.8 23.2 18.1 16.5 13.0 117  
4. 77.3 32.4 24.5 20.2 17.2 14.6   
5. 40.0 34.6 33.5 27.2 25.3 21.4 19.8  
Legends: min: minutes; mg/l: milligram per liter; No.: Number. 
 
3.3.2 Individual Plasma Levels in 60-min-group. 
 
The plasma levels of paracetamol in individual subjects in the 60-min-group are 
listed in table 4. 
 
 
Table 4. Individual plasma levels of paracetamol in 60-min-group. 
Animal 
No. 
Plasma Levels [mg/l] 60-min-group 
 15min 30min 60min 90min 120min 150min 180min 210min 
6. 24.2 29.4 28.5 21.0 17.9 18.1 14.4  
7.  20.1 37.3 22.8 30.6 28.6 25.3 23.3 
8.   33.4 37.1 27.0  23.2 20.2 19.2 
9.  18.7 24.2 17.2 24.2 20.8 19.2 17.8 
10. 12.8 33.0 48.7 39.4 32.9 27.1 23.5  
Legends: min: minutes; mg/l: milligram per liter; No.: Number. 
 
3.3.3 Mean Plasma Levels 
 
The mean plasma levels were higher in 60-min-group as compared to those in 




Table 5. Mean plasma levels in both groups. 
Group Mean plasma levels [mg/l] (Standard Deviation) 
































Legends: min: minutes; mg/l: milligram per liter; No.: Number. 
 
 
The comparison between the plasma levels of paracetamol in plasma is 


















Legends: min: minutes; mg/l: milligram per Liter.  
 







3.4 CSF Level of paracetamol 
The concentrations of paracetamol measured at regular interval in both 
groups of animals are given in the following tables. 
 
3.4.1. Individual CSF Levels in 15-min-group 
 
The individual levels of paracetamol concentration measured in CSF of 15-
min-group are given in table 6. 
 
 
Table 6. CSF levels of Paracetamol in 15-min-group. 
Animal 
No. 
CSF Levels [mg/l] 15-min-group  
 15min 30min 60min 90min 120min 150min 180min 210min 
1.         
2.  13.3 16.0 14.0 12.7 15.4 14.7 13.6 
3. 10.7 11.8 12.8 14.7 13.8 12.5 12.6  
4.    10.1 12.0 12.3   
5.   11.0 13.7 16.3 17.0 16.1  
















3.4.2. Individual CSF Levels in 60-min-group. 
 
The data obtained from individual levels of CSF concentrations of paracetamol 
in 60-min-group is listed in table 7.  
 
 
Table 7. CSF levels of Paracetamol in 60-min-group. 
Animal 
No. 
CSF Levels [mg/l]  60-min-group 
 15min 30min 60min 90min 120min 150min 180min 210min 
6.   13.3 16.1 14.8 16.9 20.0  
7.     12.5 18.5 20.2 20.5 
8.    12.6 12.2 19.8 21.0 18.1 
9.     10.0 11.6 13.5 13.0 
10.    10.8 17.7 18.3 19.3  
Legends: CSF: Cerebrospinal fluid; min: minutes; mg/l: milligram per Liter; No.: Number. 
 
 
3.4.3 Mean CSF Levels  
In the time interval between 150 and 210 minutes CSF levels were higher in 
both groups. The results of plasma and CSF levels are shown in tables 8 and 
figures 3.  
 
 
Table 8. Mean CSF levels in both groups. 
Group Mean CFS [mg/l] (Standard Deviation)  






































Legends: CSF: Cerebrospinal Fluid; mg/l: milligram per Liter. 
 




The pigs in both groups showed the comparable maximum plasma 
concentration C(Max). The C(Max) values for both the groups were as follows: 
15-min-group (median+/-SD) 35.1±17.48 and 60-min-group (median±SD) 
37±7.42 mg/l. The elimination half-lives (t ½ beta) were (median±SD) 120± 
28.72 min. in the 15-min-group and 176± 127.62min in the 60-min-group. For t 
½ beta the difference between the two groups was statistically significant 
(Mann-Whitney-U, P=0.03). The clearance (Cl) was higher in the 15-min-group 
(median±SD) 181±67 ml/l as compared to that in the 60-min-group 
(median±SD) 94.9±45.73 ml/l ( P=0.01). 
The median volumes of distribution at steady state (Vss) were comparable in 
both the groups; Vss was (median+/-SD) 31.5±8.46 l  in 15-min-group and 
25.2±8.18 l in the 60-min-group. The pigs in the 60-min-group showed a 
distinct prolongation of the elimination half-life of paracetamol compared to the 
pigs in the 15-min-group. Therefore the duration of i.v. infusion of paracetamol 
for the treatment of postoperative analgesia should be increased to achieve a 

















The individual plasma concentrations of paracetamol measured in 15-min-
group plotted against time are shown in the figures 4 to 8. 
Legends: mg/l: milligram per Liter;  min: minutes. 
 















Legends: mg/l: milligram per Liter;  min: minutes. 
 
















Legends: mg/l: milligram per Liter;  min: minutes. 
 













Legends: mg/l: milligram per Liter;  min: minutes. 
 








Legends: mg/l: milligram per Liter;  min: minutes. 
 
















The figures 9 to 13 show the individual plasma concentrations of paracetamol 
plotted against time measured in 60-min-group. 
 
 
Legends: mg/l: milligram per Liter;  min: minutes. 
 







Legends: mg/l: milligram per Liter;  min: minutes. 
 









Legends: mg/l: milligram per Liter;  min: minutes. 
 




Legends: mg/l: milligram per Liter;  min: minutes. 
 
Figure 12. Plasma levels in animal No.9 (60-min-group). 
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Legends: mg/l: milligram per Liter;  min: minutes. 
 
















The following tables show the values calculated from plasma concentrations 
of Paracetamol with the help of TopFit 2.0. 




Table 9. Elimination half-life, Mean resident time total, Volume of distribution 
at steady state, Clearance, Area under the curve and Maximum plasma 
concentrations in 15-min-group. 
Measured pharmacokinetic values in 15-min-group 
Animal No. 1 2 3 4 5 
b2 t50% (min) 86.4 135 119 120 175 
MRT-tot (min) 
116 202 177 161 258 
Vss (l) 47.6 35 31.5 23.9 25.5 
Cl (ml/min) 439 181 187 155 102 
AUC-model 
(mg/l*min) 2280 5530 5360 6450 9830 
Cmax (mg/l) 32.7 29.8 35.1 77.3 40 
Legends: AUC: Area under the curve; b2 t50%: Elimination half-life; Cl: Clearance; Cmax: 
Maximum plasma concentration; min: minutes; MRT-tot: Mean resident time total; No.: 
Number; Vss: Volume of distribution at steady state. 
 
The individual pharmacokinetic values obtained from 60-min-group are given 
in table 10 below.  
 
Table 10.  Elimination half-, Mean resident time total (MRT-tot), Volume of 
distribution at steady state, Clearance, Area under the curve and Maximum 
plasma concentration in 60-min-group. 
 
Measured pharmacokinetic values in 60-min-group 
Animal No. 6 7 8 9 10 
b2 t50% (min) 176 247 130 411 143 
MRT-tot (min) 256 383 244 615 226 
Vss (l) 30.3 25.2 23.6 38.7 18.6 
Cl (ml/min) 134 70.7 111 66.1 94.9 
AUC-model 
(mg/l*min) 7440 14100 8980 15100 10500 
Cmax (mg/l) 37.1 37 37 27.3 50.6 
Legends: AUC: Area under the curve; b2 t50%: Elimination half-life; Cl: Clearance; Cmax: 
Maximum plasma concentration; min: minutes; MRT-tot: Mean resident time total; No.: 
Number; Vss: Volume of distribution at steady state. 
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Table 11.The comparison between different pharmacological values along 
with the significance measured using the Mann-Whitney test is listed in table 
below. 
 
Comparison of calculated pharmacological values in both groups 




Groups A B A B A B A B A B A B 
























 SD 28.72 127.62 
 










0.03 0.03 0.1 0.01 0.01 0.5 
Legends: AUC: Area under the curve; b2 t50%: Elimination half-life; Cl: Clearance; Cmax: 
Maximum plasma concentration; min: minutes; MRT-tot: Mean resident time total; No.: 







4.1 Summary of the Results 
 
We studied the pharmacokinetics of intravenous paracetamol using different 
infusion rates. One of the two groups (n=5) received 1g of paracetamol over 
15 minutes and the other group (n=5) over 60 minutes.    
 
The results show that in the time interval between 60 and 180 minutes after 
starting the infusion, the plasma levels of paracetamol were found to be higher 
in the 60-min-group as compared to those in the 15-min-group. Similarly the 
levels of paracetamol in CSF in the time interval between 150 to 210 minutes 
were higher in the 60-min-group as compared to those in the 15-min-group. 
The elimination half-life of the drug was found to be longer (median+/-SD) 
176± 127.62min in 60-minutes-group as compared to 120± 28.72 min in 15-
min-group (p<0.03). The maximum plasma concentration (C max) was 
(median+/-SD) 35.1± 17.48mg/lin the 15-min-group and 37± 7.42 mg/l in the 
60-min-group (p<0.5). The clearance (Cl) was higher in the 15-min-group 
[(median±SD) 181+/-67.02 ml/l] as compared to that in the 60-min-group 
[94.9±45.73 ml/l]. The difference between the clearance was significant 
(p<0.01). The volumes of distribution at steady state (Vss) were (median±SD) 
31.5±8.46 l in 15-min-group and 25.2±8.18 l in the 60-min-group (p<0.1). 
  
 
4.2 Comparison with current literature 
 
The response to the administration of paracetamol is not directly related to the 
concentrations of the drug in blood but rather to an effect compartment. There 
exists a time delay before the drug reaches the effect compartment and the 
equilibration half-time (Teq) is approximately 1h. The effect compartment does 
not have real measurable concentrations, but concentrations equate 
approximately to those observed in the CSF. The speed of onset may be 
shortened by giving a lager initial dose or improving the absorption 
characteristics (Anderson & Gibb, 2007b). In our experiment after the i.v. 
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application of 1g paracetamol the elimination half-life of paracetamol in plasma 
was 120± 28.72 min. and after the application of the drug (1g) over 60 minutes 
it increased to 176±127.62min.The increase in the elimination half-life achieved 
after an intravenous infusion of paracetamol applied over a longer period of 
time results in a prolonged presence of the drug in plasma and effect 
compartment leading to an increased duration of its effect.  
 
A recent study (Juhl et al., 2006) performed to demonstrate the analgesic 
efficacy of intravenous paracetamol 2 g as compared to the recommended 
dose of 1 g reports that the analgesic efficacy of a 2 g starting dose of IV 
paracetamol was superior over the recommended dose of 1 g in terms of 
magnitude and duration of analgesic effect for postoperative pain following 
third molar surgery, with no significant difference between groups regarding 
safety. Beck  (Beck et al., 2000) also demonstrated that after the rectal 
application of paracetamol the analgesic doses of paracetamol can only be 
achieved after administration of twice the conventional dose. The application 
of higher doses results in higher levels of the drug in plasma and also in the 
effect compartment. That may result in a longer elimination half-life leading to 
the required analgesic effects.  
The results obtained from our study indicate that the dosage and time of 
application of i.v. paracetamol to achieve higher and prolonged concentrations 
of the substance in plasma and effect compartment needs optimization. 
Increasing the initial dose of i.v. paracetamol followed by increased repeated 
doses is reported to be beneficial for the immediate postoperative period. 
In a study Gregoire (Gregoire et al., 2007)  and colleagues demonstrated that a 
higher dose could be of interest in the immediate postoperative period when 
the pain is maximal. They used an initial dose of 2g i.v.  paracetamol followed 
by 1g doses every 6 h, leading to a total of 5 g in 24 h. Following the first 15-
min i.v. administration of paracetamol 2 g, plasma concentrations ranged from 
67.9±21.8 µ/ml (peak plasma concentration (C(max)) at the end of infusion) to 
6.2±2.3 µ/ml (trough plasma concentration (C(min)) measured just before the 
next infusion). After the repeated 1g infusions, the plasma concentrations were 
approximately 35% lower than that measured after 2g, 
 43 
In our study the median values of C(max) were 35,1mg/l in the 15-min-group 
and 37mg/l in the 60-min-group. The median values of C(max) of paracetamol 
in both groups were comparable and we used a similar dose of 1g in both the 
groups and the mode of application was i.v. infusion. The administration of the 
drug as multiple bolus doses or as an infusion over longer period of time may 
result in the presence of the drug in plasma for a prolonged time.  
 
Previous reports indicate that the analgesic effects of paracetamol correlate 
with an effect compartment rather than to the plasma levels of the drug. 
Bannwarth and colleagues (Bannwarth et al., 1992) measured the plasma and 
CSF concentrations of paracetamol after a short intravenous infusion of 
Propacetamol. The maximum CSF concentrations were observed at the 4th 
hour and the elimination half-life was calculated to be shorter in plasma (2.4h) 
than in CSF (3.2h), suggesting a possible parallel time course of the drug in 
CSF to the analgesic effect.  
Our results also support an effect compartment and fit in a two compartment 
model for the pharmacokinetics of paracetamol and the maximum CSF 
concentrations of paracetamol were observed at the 3rd hour. The mean 
elimination half-life of the drug in plasma was found to be 2.1h and 3.6h in 15-
min-group and 60-min-group respectively. 
Bannwarth applied a single dose of 1g paracetamol (Propacetamol 2g) over a 
period of 3 minutes and plasma and CSF samples were taken from 20 
minutes to 12hours. Although we used a different infusion rate and the 
experiment was carried out on animals, but comparable results were obtained. 
 
According to our results the application of i.v. paracetamol over 60 minutes 
instead of 15 minutes results in the presence of the drug in the effect 
compartment for a prolonged period and may produce a better pain 







4.3 Impact of the results  
 
The adequacy of postoperative pain control is one of the most important 
factors in determining when a patient can be safely discharged from the 
outpatient facility ((Chung et al., 1997). 
The opioid analgesics have been the main drugs used for the treatment of peri 
operative pain. However, large doses of opioid analgesics can be associated 
with an increased incidence of the postoperative complications e.g. respiratory 
depression, sedation, postoperative nausea and vomiting, pruritus, difficulty 
voiding, and ileus. It results in a delayed discharge from the hospital and with 
that associated increased total cost of treatment. The intraoperative use of 
large bolus doses or continuous infusions of potent short-acting opioid 
analgesics (e.g., alfentanil and remifentanil) may actually increase 
postoperative pain as a result of their rapid elimination and the development of 
acute tolerance (Guignard et al., 2000). 
 
Therefore the use of non-opioid analgesics as an adjuvant or as a mono 
therapy during the perioperative period is getting increasing popularity among 
the anaesthesiologists practicing in the ambulatory environment. 
The inadequate treatment of postoperative pain contributes to the patients 
suffering and may prevent rapid recovery and rehabilitation. An understanding 
and application of the basic principles of pain management can provide 
adequate analgesia for the majority of postoperative patients (d'Amours & 
Ferrante, 1996). The optimisation of postoperative pain treatment is therefore 
an important part of the therapeutic management. 
Considerations regarding the side effects of the individual analgesics like 
nausea, and respiratory depression lead to the inadequate doses of 
analgesics resulting in unnecessary patient suffering. In a French study 
performed in 96 clinics it was noted that 46.4% of postoperative patients 
suffered from severe pain; due partly to the sub therapeutic doses of opioid 
analgesics in at least 10% of patients and over half of the patients the interval 
between doses was too long (Poisson-Salomon et al., 1996).   
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The onset of analgesic action is an important factor when characterizing the 
clinical efficacy of analgesics, especially in the management of postoperative 
pain (Laska et al., 1991). 
The improvement in the management of postoperative pain leads to the 
reduction of postoperative morbidity. By reducing the complications 
associated with inadequate postoperative pain management, the hospital stay 
and the total cost of treatment can be reduced (d'Amours & Ferrante, 1996; 
Kehlet, 1997). 
 
The presently available data includes the studies showing the optimization of 
postoperative pain management. However, none of them show the 
optimization of analgesia through different infusion protocols. The studies 
concerned with the pharmacokinetics of paracetamol are still to be confirmed 
in human and animal models. 
The evaluation of the pharmacokinetics of i.v. paracetamol in our study show 
that the application of 1g of the drug as an intravenous infusion over 60 
minutes as compared to that over15 minutes is associated with a prolonged 
elimination half-life of the drug in plasma and higher levels of the drug in CSF. 
As current studies suggest CSF to be the effect compartment for the analgesic 
effects of paracetamol (Bannwarth et al 1992); optimisation of the intravenous 
application to obtain an increased CSF concentration may be of value for a 
better utilization of pharmacological effects of the drug after intravenous 





The study did not include the measurement of analgesic or antipyretic effects 
and the results obtained from an animal experiment model may not be applied 
to a human model but the data obtained from animal experiments may be 
beneficial for further studies in human.  
 
The flow of CSF was reduced to a very low level after 210 minutes that no 
further collection of CSF samples was possible. Similarly the samples of 
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plasma were not taken for a longer period than 210 minutes. The 
concentration of paracetamol measured with this method was not possible 
under the limit of the used procedure. 
For the most exact calculation of half-life kinetics long lasting measures of 
blood concentrations of the drug till it reaches the limits of the detection are 
useful. 
 
4.5 Conclusion and perspectives 
The infusion of 1g i.v. paracetamol over a 60 minutes period instead of 
recommended time of 15 minutes results in a higher plasma and CSF 
concentration. Pharmacokinetic suggests that, the analgesic effect of i.v. 
paracetamol for an infusion over 60 minutes is superior to the recommended 
infusion over 15 minutes. The infusion protocol for patients´ treatment should 
be scrutinized in randomized clinical trials.  
According to the results obtained from our study, the application of i.v. 
paracetamol for a longer duration of time for example over 2 hours instead of 
15 minutes may result in a longer period of analgesia. Increasing the dose of 
paracetamol from 1g to 2g may also produce better pain management. 
Further randomized clinical studies in humans should be performed to confirm 








Perfalgan® is a newly developed; direct inject able form of paracetamol. The 
recommended infusion rate for Perfalgan® is 1g over 15 minutes. This 
recommendation is based on the rationale that paracetamol acts centrally and 
to achieve an efficacious cerebrospinal fluid (CSF) level of paracetamol a high 
gradient between plasma and liquor is essential. 
Aim of the trial:  
Aim of the present investigation was to evaluate, whether similar efficacious 
CSF levels of Perfalgan® could be obtained after an infusion rate of 1g over 60 
minutes. 
Methods: 
Experiments were performed in 10 anaesthetized female German domestic 
pigs. The pigs were randomized either in the group with an infusion rate of 15 
minutes (n=5) or 60 minutes (n=5). In the 15-minutes-group plasma and CSF 
samples were taken 15, 30, 60, 90 120, 150, 180, and 210 minutes after 
starting the infusion. In the 60-minutes-group plasma samples were taken 60 
minutes after starting the infusion and every 30 minutes up to 210 minutes. 
CSF samples were obtained after 90, 120, 150, 180, and 210 minutes.  
Results: 
There were no differences between the groups regarding age (15-min-group: 
11 - 13 weeks; 60-min-group: 11 - 14 weeks) and body weight (15-min-group: 
38.8 – 41.7 kg; 60-min-group: 38.5 – 41.9 kg). 
The elimination half-life (t ½ beta) of the drug was found to be longer in 60-
minutes-group [(median±SD) 176± 127.62min] as compared to that in 15-min-
group [120± 28.72 min]. The clearance (Cl) was lower in the 60-min-group 
[(median±SD) 94.9±45.73 ml/l)] as compared to that in the15-min-group 
[181±67 ml/l]. The values of maximum plasma concentration (C max) were 
(median±SD) 35.1± 17.48 in the 15-min-group and 37± 7.42 mg/l in the 60-
min-group. The volumes of distribution at steady state (Vss) were (median+/-
SD) 31.5±8.46 l in 15-min-group and 25.2±8.18 l in the 60-min-group. 
Our results indicate that plasma levels are higher in the 60-minutes-group as 
compared to that in 15-minutes-group in the time interval between 60 and 180 
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minutes after starting the infusion. In the time interval between 90 and 210 
minutes CSF levels were similar in both groups.  
 
Conclusion: 
The intravenous infusion of 1g paracetamol over a period of 60 minutes 
instead of recommended duration of 15 minutes results in higher plasma and 
CSF concentrations. Pharmacokinetics suggests that, the analgesic effect of 
paracetamol for an infusion over 60 minutes is superior to the recommended 
infusion over 15 minutes. The infusion protocol for patients´ treatment should 
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